- Home
- CRGX vs GENC Comparison
CRGX vs GENC Comparison
Compare CRGX & GENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- GENC
- Stock Information
- Founded
- CRGX 2021
- GENC 1894
- Country
- CRGX United States
- GENC United States
- Employees
- CRGX N/A
- GENC N/A
- Industry
- CRGX
- GENC Construction/Ag Equipment/Trucks
- Sector
- CRGX
- GENC Industrials
- Exchange
- CRGX Nasdaq
- GENC Nasdaq
- Market Cap
- CRGX 190.0M
- GENC 210.9M
- IPO Year
- CRGX 2023
- GENC N/A
- Fundamental
- Price
- CRGX $4.20
- GENC $14.34
- Analyst Decision
- CRGX Hold
- GENC
- Analyst Count
- CRGX 7
- GENC 0
- Target Price
- CRGX $4.67
- GENC N/A
- AVG Volume (30 Days)
- CRGX 591.0K
- GENC 24.9K
- Earning Date
- CRGX 08-11-2025
- GENC 06-27-2025
- Dividend Yield
- CRGX N/A
- GENC N/A
- EPS Growth
- CRGX N/A
- GENC N/A
- EPS
- CRGX N/A
- GENC 0.99
- Revenue
- CRGX N/A
- GENC $113,166,000.00
- Revenue This Year
- CRGX $57.81
- GENC N/A
- Revenue Next Year
- CRGX N/A
- GENC N/A
- P/E Ratio
- CRGX N/A
- GENC $14.14
- Revenue Growth
- CRGX N/A
- GENC 7.70
- 52 Week Low
- CRGX $3.00
- GENC $10.80
- 52 Week High
- CRGX $25.45
- GENC $24.88
- Technical
- Relative Strength Index (RSI)
- CRGX 44.13
- GENC 48.63
- Support Level
- CRGX $4.07
- GENC $13.68
- Resistance Level
- CRGX $4.31
- GENC $15.45
- Average True Range (ATR)
- CRGX 0.17
- GENC 0.72
- MACD
- CRGX -0.03
- GENC -0.07
- Stochastic Oscillator
- CRGX 18.62
- GENC 20.54
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About GENC Gencor Industries Inc.
Gencor Industries Inc and its subsidiaries is a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company has one reporting segment, equipment for the highway construction industry. The firm's principal products include asphalt plants, combustion systems, hot mix asphalt plants, fluid heat transfer systems, and asphalt pavers.